Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , AR-711 (COVID-19).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

MARCH 2, 2021

Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021) taking place from March 6-10. Gilead Sciences, Inc. HIV Research. HCV Research.

Virus 40

Virus Treatment Science Trials 40

The Pharma Data

OCTOBER 21, 2020

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. Kimberly Smith, M.D.,

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

Drug Target Review

OCTOBER 25, 2023

Preeclampsia may present at any gestation but is more commonly encountered in the third trimester. Our findings could potentially lead to a cell therapy approach to treat those types of conditions.” A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body.

Treatment 105

Treatment Virus Research Science 105

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. The path ahead While this study is a significant stride in cancer research, it hasn’t yet led to a new cancer therapy for humans. However, cancer cells exploit mucins to support their survival.

Immune Response 116

Immune Response Research Engineering Virus 116

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

Fierce BioTech

JULY 17, 2023

png Listing Introduction In this presentation Mathias Kahl will refer about identified challenges, learnings and solutions during IDT AAV and LV manufacturing platform establishment. Sponsors are faced with a stark learning curve that, without intervention, may lead to high costs, delays, and a failure to bring their drug to patients.

Clinical Trials 52

Clinical Trials Virus Trials Therapies 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Disease 52

Drug Target Review

SEPTEMBER 28, 2023

For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. Often, DNA technology is used in the development of new therapies.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

AUGUST 18, 2020

Experts suspect this is because the pandemic virus attacks nerve cells directly involved with smell and taste sensation. Anyone with these symptoms should self-isolate and arrange to have a swab test to check if they have the virus. The nose is one of the places where Sars-CoV-2, the virus that causes Covid-19, enters the body.

Virus 52

Virus Science Therapies Research 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. 13 to 15 in Boston, will be presented in a hybrid format offering either in-person or virtual attendance. The meeting, to be held Nov. More Information. © 2020 HealthDay.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

NOVEMBER 23, 2020

Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Suspected cases presenting with compatible symptoms were tested for virological confirmation by COVID-19 PCR. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

Alta Sciences

JULY 25, 2024

Watch the poster presentation. In this eBook, discover the different requirements, procedures, and timelines based on where you choose to conduct your studies—whether in Canada, the U.S., the UK, or the EU. Read the eBook.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

It’s a paper published in the journal Science [1] that presents an atomic-scale snapshot showing the 3D structure of the spike protein on the novel coronavirus attached to a human cell surface protein called ACE2, or angiotensin converting enzyme 2. ACE2 is the receptor that the virus uses to gain entry.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

The Pharma Data

MARCH 1, 2022

We look forward to discussing this further with FDA over the coming months so that we can make this investigational new therapy available to people living with multidrug-resistant HIV as soon as possible,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

FDA 52

FDA Treatment Science Therapies 52

The Pharma Data

OCTOBER 16, 2020

Mark Hanley, CEO of VirTrial commented: “The sites we work with are excited about the opportunity to be part of the solution for a true and present need, and appreciate the benefit of being able to conduct a patient-centric study via a fully remote decentralized clinical trial while eliminating any risk to employees.”. Source link.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

JANUARY 31, 2021

Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, in the proprietary dual PRRT therapy.

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

The Pharma Data

SEPTEMBER 5, 2021

” These findings were presented at the European Respiratory Society (ERS) International Congress 2021 between September 5-8. Food and Drug Administration Breakthrough Therapy Designation was granted to tezepelumab in September 2018 for patients with severe asthma, without an eosinophilic phenotype.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

DECEMBER 28, 2020

Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

APRIL 26, 2022

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. No vaccine-related serious adverse events (SAEs) were observed.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

New Drug Approvals

JANUARY 31, 2024

BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

NIH Director's Blog: Drug Discovery

MARCH 8, 2016

Golub and colleagues produced the library by using a virus to insert a distinct DNA barcode, just 24 nucleotides long, stably into the genomes of each genetically distinct tumor cell line. It scans tiny, color-coded beads that are preprogrammed to bind to a specific barcode, providing a tally of each cell line present in a mixture.

DNA 52

DNA Drugs Small Molecule FDA Approval 52

The Pharma Data

FEBRUARY 22, 2021

Bayer AG’s decision to join forces with CureVac and help produce the vaccine is another crucial step in the fight against the virus,” said State Premier Laschet. This is particularly true in the case of cell and gene therapies, which could play a major part in improving future health care for our population.”. About Bayer.

Vaccine 40

Vaccine Production Virus Pharmaceuticals 40

The Pharma Data

OCTOBER 20, 2020

” The relevance of targeting lung localized tumors is that it could provide a means to address a significant unmet need in cancer therapy. The latest studies conducted in rats validated the previous animal studies presented at AACR. . HOUSTON , Oct. Moleculin Biotech, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Treatment Immune Response 40

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Agency IQ

JULY 26, 2024

Additional information about the meetings can be found here ; this includes meeting attachments, general agendas, minutes and presentations. NBCG-Med presented the results of the poll at the MDCG/stakeholders meeting in May. Stakeholders are largely industry groups (e.g., ECOO , HOPE , ESC ) and patients (e.g.,

Laboratories 40

Laboratories Regulations Virus Production 40

The Pharma Data

JANUARY 31, 2021

While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. Results from the NAVIGATOR trial will be presented at an upcoming medical meeting. Amgen Inflammation Amgen brings therapies to millions of people with inflammatory diseases, with a focus on serving unmet patient needs.

Trials 52

Trials Production Clinical Trials Government 52

Elrig

FEBRUARY 23, 2023

You’ll get an overview of this info-packed event, the lowdown on why you really can’t afford to miss it , and a sneak peek at the presentation topics from our keynote speakers: Altos Labs’ Dr Ken Raj and Dr Ron Weiss of the Massachusetts Institute of Technology (MIT). You could even get the chance to present in the main speaker sessions.

Research 40

Research Disease Science Drugs 40

Metabolite Tales Blog

JULY 5, 2023

Figure 1 Metabolism of simeprevir Glecaprevir (ABT493/A-1282576) is another antiviral drug for the treatment of chronic hepatitis C which also undergoes limited CYP3A4/5 mediated metabolism in vitro , and for which all human metabolites were present in at least one animal species. Ayushi Jain and Khalid Mumtaz, 2022.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Figure 1 Metabolism of simeprevir Glecaprevir (ABT493/A-1282576) is another antiviral drug for the treatment of chronic hepatitis C which also undergoes limited CYP3A4/5 mediated metabolism in vitro , and for which all human metabolites were present in at least one animal species. Ayushi Jain and Khalid Mumtaz, 2022.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

The Pharma Data

DECEMBER 21, 2020

Detailed results from the SOURCE trial will be presented at a future medical meeting. In September 2018 , the US Food and Drug Administration granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype. Further analyses of the data are ongoing.

Trials 40

Trials Production Clinical Trials Therapies 40